INDP Insider Trading

Insider Ownership Percentage: 27.10%
Insider Buying (Last 12 Months): $142,052.32
Insider Selling (Last 12 Months): $0.00

Indaptus Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Indaptus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Indaptus Therapeutics Share Price & Price History

Current Price: $2.06
Price Change: Price Decrease of -0.1392 (-6.33%)
As of 03/1/2024 02:25 PM ET

This chart shows the closing price history over time for INDP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Indaptus Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/14/2023Glen R AndersonMajor ShareholderBuy23,934$2.34$56,005.561,190,400View SEC Filing Icon  
8/10/2023Glen R AndersonMajor ShareholderBuy44,354$1.94$86,046.761,131,402View SEC Filing Icon  
12/1/2022Boyan Vesselinov LitchevInsiderBuy500$1.87$935.001,150View SEC Filing Icon  
11/22/2022Boyan Vesselinov LitchevInsiderBuy500$1.83$915.00650View SEC Filing Icon  
11/21/2022Jeffrey A. MecklerCEOBuy9,600$1.90$18,240.0075,374View SEC Filing Icon  
11/18/2022Jeffrey A. MecklerCEOBuy400$1.76$704.0065,774View SEC Filing Icon  
9/8/2022Jeffrey A. MecklerCEOBuy10,308$2.80$28,862.4065,374View SEC Filing Icon  
9/7/2022Walt Addison LinscottInsiderBuy150$2.62$393.00150View SEC Filing Icon  
6/6/2022Jeffrey A. MecklerCEOBuy19,727$2.63$51,882.0145,374View SEC Filing Icon  
3/2/2022Boyan Vesselinov LitchevInsiderBuy50$4.09$204.50150View SEC Filing Icon  
1/31/2022Boyan Vesselinov LitchevInsiderBuy100$4.65$465.00100View SEC Filing Icon  
1/31/2022Michael James NewmanDirectorSell5,870$5.00$29,350.00View SEC Filing Icon  
11/18/2021Jeffrey A. MecklerCEOBuy11,187$5.82$65,108.34View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Indaptus Therapeutics (NASDAQ:INDP)

21.24% of Indaptus Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INDP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Indaptus Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/15/2024Citadel Advisors LLC16,518$29K0.0%N/A0.197%Search for SEC Filing on Google Icon
11/9/2023Investment House LLC102,849$0.28M0.0%-5.0%1.224%Search for SEC Filing on Google Icon
8/25/2023Strategy Asset Managers LLC45,336$87K0.0%-18.1%0.540%Search for SEC Filing on Google Icon
8/8/2023Investment House LLC108,282$0.21M0.0%+13.2%1.289%Search for SEC Filing on Google Icon
10/11/2022Strategy Asset Managers LLC55,336$0.12M0.0%N/A0.670%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC19,600$51K0.0%N/A0.237%Search for SEC Filing on Google Icon
7/22/2022Stratos Wealth Partners LTD.26,832$70K0.0%-97.7%0.325%Search for SEC Filing on Google Icon
5/16/2022State Street Corp19,473$78K0.0%N/A0.236%Search for SEC Filing on Google Icon
5/13/2022Northern Trust Corp10,296$41K0.0%N/A0.125%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.242,235$0.97M0.0%+18.7%2.933%Search for SEC Filing on Google Icon
4/26/2022Stratos Wealth Partners LTD.1,188,356$4.75M0.1%-14.4%14.389%Search for SEC Filing on Google Icon
2/9/2022Investment House LLC95,629$0.55M0.0%+272.8%1.167%Search for SEC Filing on Google Icon
1/14/2022Stratos Wealth Partners LTD.1,388,356$7.91M0.2%N/A16.952%Search for SEC Filing on Google Icon
11/15/2021Marshall Wace LLP12,780$100K0.0%N/A0.236%Search for SEC Filing on Google Icon
10/25/2021Harel Insurance Investments & Financial Services Ltd.2,958$25K0.0%N/A0.055%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Indaptus Therapeutics logo
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Read More on Indaptus Therapeutics

Today's Range

Now: $2.06
Low: $2.00
High: $2.20

50 Day Range

MA: $1.78
Low: $1.63
High: $2.20

52 Week Range

Now: $2.06
Low: $1.50
High: $4.08

Volume

20,997 shs

Average Volume

14,947 shs

Market Capitalization

$17.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Who are the company insiders with the largest holdings of Indaptus Therapeutics?

Indaptus Therapeutics' top insider shareholders include:
  1. Glen R Anderson (Major Shareholder)
  2. Jeffrey A Meckler (CEO)
  3. Boyan Vesselinov Litchev (Insider)
  4. Walt Addison Linscott (Insider)
Learn More about top insider investors at Indaptus Therapeutics.

Who are the major institutional investors of Indaptus Therapeutics?

Indaptus Therapeutics' top institutional shareholders include:
  1. Citadel Advisors LLC — 0.20%
Learn More about top institutional investors of Indaptus Therapeutics stock.

Which institutional investors are buying Indaptus Therapeutics stock?

During the last quarter, INDP stock was acquired by institutional investors including:
  1. Citadel Advisors LLC
In the last year, these company insiders have bought Indaptus Therapeutics stock:
  1. Glen R Anderson (Major Shareholder)
  2. Jeffrey A Meckler (CEO)
  3. Boyan Vesselinov Litchev (Insider)
  4. Walt Addison Linscott (Insider)
Learn More investors buying Indaptus Therapeutics stock.